Y-Mabs Therapeutics Inc (YMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,629 | -21,427 | -20,439 | -12,692 | -6,390 |
| Depreciation Amortization | 159 | 735 | 574 | 406 | 182 |
| Accounts receivable | 1,866 | -9,923 | -6,343 | -6,587 | -6,171 |
| Accounts payable and accrued liabilities | 176 | -6,856 | -6,196 | -6,149 | -4,771 |
| Other Working Capital | -1,345 | -19,734 | -10,292 | -13,718 | -11,764 |
| Other Operating Activity | 2,296 | 29,973 | 23,500 | 20,882 | 15,790 |
| Operating Cash Flow | $-3,477 | $-27,232 | $-19,196 | $-17,858 | $-13,124 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $0 | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 588 | 100 | 0 | 0 | N/A |
| Financing Cash Flow | $588 | $100 | $0 | $0 | $N/A |
| Exchange Rate Effect | 1 | 7 | 5 | 5 | -9 |
| Beginning Cash Position | 78,637 | 105,762 | 105,762 | 105,762 | 105,762 |
| End Cash Position | 75,749 | 78,637 | 86,571 | 87,909 | 92,629 |
| Net Cash Flow | $-2,888 | $-27,125 | $-19,191 | $-17,853 | $-13,133 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,477 | -27,232 | -19,196 | -17,858 | -13,124 |
| Free Cash Flow | -3,477 | -27,232 | -19,196 | -17,858 | -13,124 |